| Candice A Ruby, MD | |
|
10800 Magnolia Ave, Riverside, CA 92505-3043 | |
| (909) 353-2000 | |
| Not Available |
| Full Name | Candice A Ruby |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 26 Years |
| Location | 10800 Magnolia Ave, Riverside, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407904451 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | A79069 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital, Riverside | Riverside, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
In the decade since the federal government's electronic health record (EHR) initiatives first became law, nearly all U.S. hospitals have adopted some form of EHR technology.
Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal Antibody (RabMAb®) technology, today announced that the Company has signed a contract with SAIC Frederick, Inc., operating under contract with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer (CPTC) program (www.proteomics.cancer.gov).
During embryonic development, cells migrate to their eventual location in the adult body plan and begin to differentiate into specific cell types. Thanks to new research at the University of Pennsylvania, there is new insight into how these processes regulate tissues formation in the heart.
Following a nationwide call for support for the NHS workforce, UEA students and staff have responded in their numbers, from undertaking placements to training former healthcare professionals who are re-joining the service at this time of national emergency.
MedImmune has announced that it has licensed its proprietary reverse genetics intellectual property to sanofi pasteur, the vaccines business of the sanofi-aventis Group, to support the development and construction of new vaccine strains to produce human seasonal, pre-pandemic and pandemic influenza vaccines.
› Verified 3 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
In the decade since the federal government's electronic health record (EHR) initiatives first became law, nearly all U.S. hospitals have adopted some form of EHR technology.
Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal Antibody (RabMAb®) technology, today announced that the Company has signed a contract with SAIC Frederick, Inc., operating under contract with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer (CPTC) program (www.proteomics.cancer.gov).
During embryonic development, cells migrate to their eventual location in the adult body plan and begin to differentiate into specific cell types. Thanks to new research at the University of Pennsylvania, there is new insight into how these processes regulate tissues formation in the heart.
Following a nationwide call for support for the NHS workforce, UEA students and staff have responded in their numbers, from undertaking placements to training former healthcare professionals who are re-joining the service at this time of national emergency.
MedImmune has announced that it has licensed its proprietary reverse genetics intellectual property to sanofi pasteur, the vaccines business of the sanofi-aventis Group, to support the development and construction of new vaccine strains to produce human seasonal, pre-pandemic and pandemic influenza vaccines.
› Verified 3 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316979834 PECOS PAC ID: 6002729175 Enrollment ID: O20040126000823 |
News Archive
In the decade since the federal government's electronic health record (EHR) initiatives first became law, nearly all U.S. hospitals have adopted some form of EHR technology.
Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal Antibody (RabMAb®) technology, today announced that the Company has signed a contract with SAIC Frederick, Inc., operating under contract with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer (CPTC) program (www.proteomics.cancer.gov).
During embryonic development, cells migrate to their eventual location in the adult body plan and begin to differentiate into specific cell types. Thanks to new research at the University of Pennsylvania, there is new insight into how these processes regulate tissues formation in the heart.
Following a nationwide call for support for the NHS workforce, UEA students and staff have responded in their numbers, from undertaking placements to training former healthcare professionals who are re-joining the service at this time of national emergency.
MedImmune has announced that it has licensed its proprietary reverse genetics intellectual property to sanofi pasteur, the vaccines business of the sanofi-aventis Group, to support the development and construction of new vaccine strains to produce human seasonal, pre-pandemic and pandemic influenza vaccines.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Candice A Ruby, MD 10800 Magnolia Ave, Riverside, CA 92505-3043 Ph: (909) 353-2000 | Candice A Ruby, MD 10800 Magnolia Ave, Riverside, CA 92505-3043 Ph: (909) 353-2000 |
News Archive
In the decade since the federal government's electronic health record (EHR) initiatives first became law, nearly all U.S. hospitals have adopted some form of EHR technology.
Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal Antibody (RabMAb®) technology, today announced that the Company has signed a contract with SAIC Frederick, Inc., operating under contract with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer (CPTC) program (www.proteomics.cancer.gov).
During embryonic development, cells migrate to their eventual location in the adult body plan and begin to differentiate into specific cell types. Thanks to new research at the University of Pennsylvania, there is new insight into how these processes regulate tissues formation in the heart.
Following a nationwide call for support for the NHS workforce, UEA students and staff have responded in their numbers, from undertaking placements to training former healthcare professionals who are re-joining the service at this time of national emergency.
MedImmune has announced that it has licensed its proprietary reverse genetics intellectual property to sanofi pasteur, the vaccines business of the sanofi-aventis Group, to support the development and construction of new vaccine strains to produce human seasonal, pre-pandemic and pandemic influenza vaccines.
› Verified 3 days ago
Sang Kun Yim, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 7117 Brockton Ave, Riverside, CA 92506 Phone: 951-683-6370 | |
Sarah Chae, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4646 Brockton Ave Ste 201, Riverside, CA 92506 Phone: 951-585-1800 Fax: 951-585-1801 | |
Alina S Popa, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 4445 Magnolia Ave, Riverside, CA 92501 Phone: 951-788-3636 | |
Richard M. Bradburne, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Shelly C. Thio, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Fawaz Gailani, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 10800 Magnolia Ave, Riverside, CA 92505 Phone: 909-353-2000 | |
Andrew Duke, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 4445 Magnolia Ave, Riverside, CA 92501 Phone: 951-788-3000 |